Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

FDMT stock hub

4D Molecular Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

FDMTis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
530.1M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
FDMT
In the news

Latest news · FDMT

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROE-34.9
P25 -105.6P50 -46.5P75 -3.1
ROIC-22.8
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All FDMT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
199
Groups with data
11
Currency
USD
Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

25
MetricValue
Cik
0001650648
Company name
4D Molecular Therapeutics, Inc.
Country
United States
Country code
US
Cusip
35104E100
Employees
196
Employees Change
-31%
Employees Change Percent
-13.66
Enterprise value
$93M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2020-12-11
Isin
US35104E1001
Last refreshed
2026-05-10
Market cap
$530.1M
Market cap category
Small-Cap
Price
$10.14
Price currency
USD
Rev Per Employee
450,214.29x
Sector
Healthcare
Sic
2836
Symbol
FDMT
Website
https://www.4dmoleculartherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

7
MetricValue
Earnings Yield
-30.35%
EV Sales Forward
4.41x
EV/Sales
1.05x
FCF yield
-24.52%
P/B ratio
1.17x
P/S ratio
6.01x
PS Forward
25.15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

15
MetricValue
EBIT Margin
-199.84%
EBITDA Margin
-194.28%
Gross margin
-118.15%
Gross Profit
$-104.3M
Net Income
$-160.9M
Net Income Growth Years
1%
Pretax Margin
-182.34%
Profit Margin
-182.34%
Profit Per Employee
$-820,903
ROA
-21.43
Roa5y
-20.62
ROCE
-37.56
ROE
-34.92
Roe5y
-33.63
ROIC
-22.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

10
MetricValue
Cagr1y
225.79%
Cagr3y
-15.72%
Cagr5y
-20.93%
EPS Growth Years
1
Revenue Growth
383,560.87x
Revenue Growth Q
21,664.29x
Revenue Growth Quarters
4x
Revenue Growth Years
1x
Revenue Growth3 Y
241.89x
Revenue Growth5 Y
48.85x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

18
MetricValue
Asset Turnover
$0.17
Assets
$512.9M
Cash
$390.9M
Current Assets
$405.4M
Current Liabilities
$43.4M
Debt
$20.5M
Debt Equity
$0.05
Equity
$451.8M
Liabilities
$61.1M
Long Term Assets
$107.5M
Long Term Liabilities
$17.7M
Net Cash
$437.1M
Net Cash By Market Cap
$82.46
Net Cash Growth
0.58%
Net Debt Equity
$-0.97
Tangible Book Value
$451.8M
Tangible Book Value Per Share
$8.64
WACC
18.7

Liquidity

Current-asset coverage and working-capital efficiency metrics.

5
MetricValue
Current ratio
9.34
Net Working Capital
$-23.4M
Quick ratio
9.01
Working Capital
$362M
Working Capital Turnover
$0.26

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-9.81%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

37
MetricValue
1Y total return
225.52%
200-day SMA
8.79
3Y total return
-40.14%
50-day SMA
9.37
50-day SMA vs 200-day SMA
50over200
5Y total return
-69.09%
All Time High
55.11
All Time High Change
-81.6%
All Time High Date
2021-02-11
All Time Low
2.24
All Time Low Change
353.69%
All Time Low Date
2025-04-09
ATR
0.6
Beta
2.76
Beta1y
0.29
Beta2y
0.78
Ch YTD
35.2
High
10.16
High52
12.34
High52 Date
2025-10-28
High52ch
-17.83%
Low
9.06
Low52
3
Low52 Date
2025-05-09
Low52ch
238%
Ma50ch
8.21%
Price vs 200-day SMA
15.42%
RSI
56.51
RSI Monthly
48.87
RSI Weekly
57.2
Sharpe ratio
1.68x
Sortino ratio
2.98
Total Return
-9.81%
Tr YTD
35.2
Tr1m
-0.98%
Tr1w
11.55%
Tr3m
12.79%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

13
MetricValue
Analyst Count
7
Analyst Count Top
3
Analyst Price Target Top
$27.67
Analyst Ratings
Strong Buy
Analyst Ratings Top
Strong Buy
Earnings EPS Estimate
$-0.99
Earnings Revenue Estimate
2,824,000x
Earnings Revenue Estimate Growth
20,071.43x
Operating Income
$-176.3M
Operating margin
-199.8
Price target
$31.71
Price Target Change
$213
Price Target Change Top
$173

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

10
MetricValue
Float
36,484,070%
Float Percent
69.79%
Shares Insiders
3.55%
Shares Institutions
76.59%
Shares Out
52,276,254
Shares Qo Q
6.49%
Shares Yo Y
9.81%
Short Float
31.57%
Short Ratio
14.07
Short Shares
22.04

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

57
MetricValue
Adjusted FCF
$-149.5M
Average Volume
684,821.15x
Bv Per Share
8.64
CAPEX
$-536,000
Ch1m
-0.98
Ch1w
11.55
Ch1y
225.5
Ch3m
12.79
Ch3y
-40.14
Ch5y
-69.09
Ch6m
-3.43
Change
2.11%
Change From Open
11.67
Close
9.93
Days Gap
-8.56
Depreciation Amortization
4,912,000
Dollar Volume
6,368,072.1
Earnings Date
2026-05-07
Earnings Time
amc
EBIT
$-176.3M
EBITDA
$-171.4M
EPS
$-2.64
F Score
2
FCF
$-130M
FCF EV Yield
-139.79x
FCF Per Share
$-2.49
Financing CF
124,444,000
Fiscal Year End
December
Founded
2,013
Investing CF
-56,033,000
Ipr
-55.91
Iprfo
-74.65
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-05-07
Last Report Date
2026-03-31
Last Split Type
Never
Last10k Filing Date
2026-03-18
Ma150
9.51
Ma150ch
6.67%
Ma20
9.7
Ma20ch
4.57%
Net CF
-61,038,000
Next Earnings Date
2026-08-10
Open
9.08
Optionable
Yes
Position In Range
98.18
Ppne
30,944,000
Price Date
2026-05-08
Ptbv Ratio
1.17
Relative Volume
0.92x
Revenue
88,242,000x
SBC By Revenue
22.08x
Share Based Comp
19,483,000
Tr6m
-3.43%
Us State
California
Volume
628,015
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does FDMT pay a dividend?

Capital-return profile for this ticker.

Performance

FDMT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+225.5%
S&P 500 1Y: n/a
3Y total return
-40.1%
S&P 500 3Y: n/a
5Y total return
-69.1%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns FDMT?

Insider, institutional, and short-interest positioning.

Institutional ownership
+76.6%
Float: +69.8% of shares outstanding
Insider ownership
+3.6%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+31.6%
14.1 days to cover
Y/Y dilution
+9.8%
Negative means the company is buying back shares.
Technical

FDMT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
56.5
Neutral momentum band
Price vs 200-day MA
+15.4%
50/200-day relationship not available
Beta (5Y)
2.76
More volatile than the market
Sharpe ratio
1.68
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About FDMT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current FDMT stock rating?

4D Molecular Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full FDMT analysis?

The full report lives at /stocks/FDMT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for FDMT?

The latest report frames FDMT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the FDMT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.